Our studies are based on the hypothesis that targeting PR along with ER should more effectively reduce breast cancer cell growth than does treatment with an antiestrogen, because progesterone, like estrogen, is mitogenic in the breast [53] and drives mammary tumor proliferation in multiple model systems. The gene discussed is ESR1; the disease is breast carcinoma.